当前位置: X-MOL 学术Mov. Disord. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Effects of the Coronavirus Disease 2019 Pandemic on Motor Symptoms in Parkinson's Disease: An Observational Study
Movement Disorders ( IF 7.4 ) Pub Date : 2021-08-25 , DOI: 10.1002/mds.28766
Mitsuhiro Kainaga 1 , Yuichiro Shirota 1, 2 , Satoshi Kodama 1 , Tatsushi Toda 1 , Masashi Hamada 1
Affiliation  

It is becoming clear that many patients with Parkinson's disease (PD) are experiencing subjective worsening of motor symptoms during the coronavirus disease 2019 (COVID-19) pandemic.1 However, little evidence using established quantitative scales is available on longitudinal changes in motor symptoms during the pandemic. We therefore evaluated changes in Movement Disorder Society Unified Parkinson's Disease Rating Scale, Part III (MDS-UPDRS-III), scores during the pandemic.

We included PD patients who continuously visited the Department of Neurology outpatient clinic, The University of Tokyo Hospital, and whose MDS-UPDRS-III (ON) scores and levodopa equivalent daily doses (LEDDs) from May 2019 to October 2020 and those at the last visit before May 2019 were available in their medical records. The observational period was divided into six subperiods of 3 months each. The latter three subperiods were considered part of the pandemic, as the Japanese public began to be urged to stay home from February 2020 after the first infected patient was reported on January 16.2 Changes in MDS-UPDRS-III scores from baseline (ΔMDS-UPDRS-III) were averaged for each subperiod. Patients in each subperiod were classified according to the ΔMDS-UPDRS-III values. A ΔMDS-UPDRS-III value between −3 and +4 was considered a minimal clinically important difference (MCID).3 Patients were also categorized according to LEDD changes (increased, maintained, and decreased) during the pre-pandemic and pandemic periods. This study was approved by the ethics board of the Graduate School of Medicine and Faculty of Medicine, The University of Tokyo (approval registration number 2339-4).

Forty-four patients were enrolled. The mean age was 69.4 ± 9.1 years, and 22 (50.0%) were female. Thirty-nine (88.6%) showed Hoehn & Yahr stage 1 or 2 at baseline. They had a mean disease duration of 6.7 ± 6.5 years, a mean MDS-UPDRS-III score (ON) of 15.8 ± 9.3, and a mean LEDD of 480.5 ± 277.1 mg. During the pandemic, the mean MDS-UPDRS-III and proportion of patients with worsening motor symptoms (above MCID) were significantly higher than those at baseline (Fig. 1A,B). Furthermore, the number of patients whose LEDDs were increased every 9 months increased significantly after the pandemic outbreak (Fig. 1C).

image
FIG 1
Open in figure viewerPowerPoint
(A) Mean change in MDS-UPDRS-III scores toward baseline (ΔMDS-UPDRS-III) in each subperiod. Whereas there was no significant change in the subperiods before the pandemic (ΔMDS-UPDRS-III = 0.1 ± 3.3, −0.4 ± 4.3, 1.0 ± 4.5, respectively; Wilcoxon's signed-rank test compared to baseline, not significant), the score was significantly higher during the pandemic subperiods (ΔMDS-UPDRS-III = 3.4 ± 4.7, 3.2 ± 5.2, 3.6 ± 7.0, respectively; *P < 0.001). (B) Distribution of ΔMDS-UPDRS-III values at each subperiod. The proportion of patients with worsening motor symptoms (groups in yellow, orange, and red) was significantly higher in the pandemic subperiods than in the pre-pandemic subperiods (Wilcoxon's rank-sum test compared to baseline, *P < 0.01). (C) Distribution of LEDD (levodopa equivalent daily dose) changes during each period. The proportion of patients whose LEDDs increased over 9 months was significantly higher after the pandemic outbreak than before the pandemic (pre-pandemic, 21%; pandemic, 46%; Wilcoxon's rank-sum test, *P < 0.05). The number of patients receiving each drug class at baseline was as follows: dopamine precursors, 40 (90.0%); dopamine agonists, 20 (45.5%); monoamine oxidase-B (MAO-B) inhibitors, 11 (25.0%); catechol-O-methyl transferase (COMT) inhibitors, 10 (22.7%); and others, 17 (38.6%). LEDD, levodopa equivalent daily dose; MDS-UPDRS-III, Movement Disorder Society Unified Parkinson's Disease Rating Scale, Part III; SD, standard deviation. [Color figure can be viewed at wileyonlinelibrary.com]

We found that about 40% of PD patients showed ΔMDS-UPDRS-III above MCID during the pandemic in Tokyo and required increased medication compared with the pre-pandemic period. Because this was a retrospective study with a small sample size without the evaluation of nonmotor symptoms, we cannot comment on the exact reason for this. It is reasonable, however, to assume that people reduced their activity levels despite the lack of legal penalties in Japan for going out,2 were staying in a confined space,4, 5 and experienced prolonged psychological stress, which may have exacerbated PD motor symptoms by reducing dopaminergic medication efficacy.6, 7 Alternatively, the worsening status during the pandemic may be related to disease progression, independent of reduced activity levels or psychological stress.

In conclusion, about 40% of PD patients showed exacerbation of motor symptoms. Careful and continuous evaluation and optimal drug adjustment are important for PD patients during a pandemic.



中文翻译:

2019 年冠状病毒病大流行对帕金森病运动症状的影响:一项观察性研究

很明显,在 2019 年冠状病毒病 (COVID-19) 大流行期间,许多帕金森病 (PD) 患者的运动症状出现主观恶化。1然而,关于大流行期间运动症状的纵向变化,几乎没有证据使用既定的定量尺度。因此,我们评估了大流行期间运动障碍协会统一帕金森病评定量表第三部分 (MDS-UPDRS-III) 分数的变化。

我们纳入了从 2019 年 5 月至 2020 年 10 月连续访问东京大学医院神经内科门诊、MDS-UPDRS-III (ON) 评分和左旋多巴等效日剂量 (LEDD) 的 PD 患者,以及最后2019 年 5 月之前的访问可在他们的病历中找到。观察期分为六个子期,每个子期为 3 个月。后三个阶段被认为是大流行的一部分,因为在 1 月 16报告了第一例感染患者后,日本公众从 2020 年 2 月开始被敦促留在家中。2MDS-UPDRS-III 评分相对于基线的变化 (ΔMDS-UPDRS-III) 对每个子周期进行平均。每个亚时期的患者根据ΔMDS-UPDRS-III值进行分类。-3 和 +4 之间的 ΔMDS-UPDRS-III 值被认为是最小的临床重要差异 (MCID)。3还根据大流行前和大流行期间 LEDD 的变化(增加、维持和减少)对患者进行了分类。本研究获得了东京大学医学研究生院和医学部伦理委员会的批准(批准注册号 2339-4)。

招募了 44 名患者。平均年龄为 69.4 ± 9.1 岁,女性 22 (50.0%)。39 人 (88.6%) 在基线时显示 Hoehn & Yahr 1 期或 2 期。他们的平均病程为 6.7 ± 6.5 年,平均 MDS-UPDRS-III 评分 (ON) 为 15.8 ± 9.3,平均 LEDD 为 480.5 ± 277.1 mg。在大流行期间,平均 MDS-UPDRS-III 和运动症状恶化(MCID 以上)的患者比例显着高于基线(图 1A、B)。此外,大流行爆发后 LEDD 每 9 个月增加一次的患者数量显着增加(图 1C)。

图片
图。1
在图形查看器中打开微软幻灯片软件
( A ) 在每个子周期中 MDS-UPDRS-III 得分相对于基线 (ΔMDS-UPDRS-III) 的平均变化。而在大流行之前的亚期间没有显着变化(分别为 ΔMDS-UPDRS-III = 0.1 ± 3.3、-0.4 ± 4.3、1.0 ± 4.5;Wilcoxon 的符号秩检验与基线相比,不显着),得分为在大流行亚期间显着更高(ΔMDS-UPDRS-III = 3.4 ± 4.7、3.2 ± 5.2、3.6 ± 7.0;* P  < 0.001)。( B ) ΔMDS-UPDRS-III 值在每个子周期的分布。运动症状恶化(黄色、橙色和红色组)的患者比例在大流行亚时期显着高于大流行前亚时期(Wilcoxon 秩和检验与基线相比,* P < 0.01)。(C)LEDD(左旋多巴等效日剂量)分布在每个时期的变化。大流行爆发后 9 个月内 LEDD 增加的患者比例显着高于大流行前(大流行前,21%;大流行,46%;Wilcoxon 秩和检验,* P  < 0.05)。基线时接受每种药物类别的患者人数如下:多巴胺前体,40 (90.0%);多巴胺激动剂,20 (45.5%);单胺氧化酶-B (MAO-B) 抑制剂,11 (25.0%);儿茶酚-O-甲基转移酶 (COMT) 抑制剂,10 (22.7%);和其他人,17 (38.6%)。LEDD,左旋多巴等效日剂量;MDS-UPDRS-III,运动障碍协会统一帕金森病评定量表,第三部分;SD,标准差。[彩色图可在 wileyonlinelibrary.com 上查看]

我们发现,在东京大流行期间,大约 40% 的 PD 患者表现出高于 MCID 的 ΔMDS-UPDRS-III,与大流行前相比,需要增加药物治疗。因为这是一项小样本量的回顾性研究,没有评估非运动症状,我们无法评论其确切原因。然而,可以合理地假设,尽管日本没有对外出进行法律处罚,但人们减少了他们的活动水平,2人呆在密闭空间中,4、5并经历了长时间的心理压力,这可能加剧了 PD 运动症状通过降低多巴胺能药物的疗效。6、7 或者,大流行期间的恶化状态可能与疾病进展有关,与活动水平降低或心理压力无关。

总之,大约 40% 的 PD 患者表现出运动症状的恶化。在大流行期间,仔细和持续的评估和最佳的药物调整对于 PD 患者很重要。

更新日期:2021-08-25
down
wechat
bug